Acknowledgment of the Reviewers of Drugs and Drug Candidates in 2023

In recognizing the exceptional efforts of our reviewers in 2023, we express our sincere gratitude for upholding the high standards of Drugs and Drug Candidates. Their commitment ensured the rigorous peer review that is integral to quality academic publishing.

In 2023, Drugs and Drug Candidates received 217 review reports, from 201 reviewers. This past year, we worked with reviewers from 41 countries and regions, reflecting the diversity in our collaboration with research communities. Their dedication shapes scholarly discourse and advances global research. The editorial team expresses gratitude for the vital role played by each reviewer in the Drugs and Drug Candidates family throughout 2023, and we look forward to their continued support in 2024.

The following are the reviewers who have consented to show their names: